Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung ... low levels of PD-L1 expression (<1%), said ...

Amgen has its first direct competition in the KRAS inhibitor class ... to plan a phase 3 trial as a first-line NSCLC therapy in patients with low PD-L1 expression. While going after a PD-L1 ...

Next-generation gene sequencing revealed pathogenic mutations in KDM6A and KRAS. In summary, we present an interesting case of B-lymphoblastic leukemia with unusual surface light chain expression ...

The researchers also discovered that "Galectin-1 can regulate gene expression ... fibroblast cell lines, investigating the effects of inhibiting both the protein and the KRAS gene, and observed ...

The researchers also discovered that "Galectin-1 can regulate gene expression ... fibroblast cell lines, investigating the effects of inhibiting both the protein and the KRAS gene, and observed ...